Fruzaqla Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Fruquintinib

Indications/Uses

Adult patients w/ metastatic colorectal cancer who have been previously treated w/ fluoropyrimidine-, oxaliplatin- & irinotecan-based chemotherapy, an anti-VEGF agent & if RAS wild-type, an anti-EGFR agent.

Dosage/Direction for Use

5 mg once daily at approx the same time each day for 21 consecutive days followed by 7-day rest period to comprise a complete cycle of 28 days.

Administration

May be taken with or without food: Swallow whole.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EK04 - fruquintinib ; Belongs to the class of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Fruzaqla cap 1 mg

Packing/Price

1's

Form

Fruzaqla cap 5 mg

Packing/Price

1's

Fruzaqla

fruquintinib

Manufacturer:

STA Pharmaceutical